Afrezza: Fast-Acting Inhaled Insulin

Simple item page
dc.contributor.authorAschenbrenner, Diane S.
dc.contributor.departmentSandra R. Berman School of Nursing and Health Professionsen_US
dc.contributor.programNursingen_US
dc.date.accessioned2017-09-27T20:07:07Z
dc.date.available2017-09-27T20:07:07Z
dc.date.issued2014-10
dc.description.abstractAfrezza (insulin human) is a newly approved fast-acting inhaled insulin. It can be used in treating type 1 diabetes when added to a long-acting insulin; in studies, patients with type 2 diabetes used it in combination with oral antidiabetic therapy. Afrezza will be available in 2015. Afrezza is taken before meals using a small, specially designed inhaler. Patients should be carefully assessed for lung disease prior to starting Afrezza therapy. Chronic obstructive pulmonary disease and asthma are contraindications to use. Lung function can deteriorate after therapy begins.en_US
dc.description.urihttps://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=107830773&site=eds-live&scope=siteen_US
dc.format.extent2 pagesen_US
dc.genrejournal articlesen_US
dc.identifierdoi:10.13016/M2C24QN9T
dc.identifier.citationAschenbrenner, D. S. (2014). Afrezza: Fast-acting inhaled insulin. American Journal Of Nursing, 114(10), 22-23. doi:10.1097/01.NAJ.0000454844.50727.76en_US
dc.identifier.urihttp://dx.doi.org/10.1097/01.NAJ.0000454844.50727.76
dc.identifier.urihttp://hdl.handle.net/11603/5650
dc.language.isoen_USen_US
dc.publisherAmerican Journal of Nursingen_US
dc.titleAfrezza: Fast-Acting Inhaled Insulinen_US
dc.typeTexten_US

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Stevenson University Faculty and Staff Works